Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
Mundipharma has entered into a distribution partnership with Egis Pharmaceuticals for its Pelmeg (pegfilgrastim) biosimilar. The agreement covers countries in central and eastern Europe (CEE) where Mundipharma does not have a direct commercial presence: Hungary, Romania, Latvia and Lithuania.
“Egis is one of the leading branded generic companies in the CEE and Commonwealth of Independent States (CIS) regions," Mundipharma...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
